LAWRENCE, Mass. and SEATTLE, March 8, 2013 /PRNewswire/ -- ADC 2013 Booth 417 -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it will host a special educational event at the 33rd Annual Dialysis Conference (ADC) on Sunday, March 10, 2013 featuring celebrity and former NxStage System One™ user Stephen Furst. The event highlights System One dialyzor experiences in achieving work-life-dialysis balance with NxStage therapy. The events at ADC bring together renal care leaders and patients to discuss ways to improve the lives of and care for people with End Stage Renal Disease (ESRD).
The educational discussion with actor and director Stephen Furst, former NxStage user Joe Collins and current NxStage dialyzor Dr. George Williams, will focus on the health and lifestyle benefits of more frequent home hemodialysis with the NxStage System One. The session will also discuss work-life balance as a dialysis patient, with each participant sharing the role of the NxStage System One in providing the flexibility to continue working in their distinct and diverse fields, from the entertainment industry to law enforcement and healthcare. While 64 percent of the general population aged 18 to 55 works, only 21 percent of hemodialysis patients are able to work three months after therapy has begun. Yet clinical data and other reports suggest that more frequent home hemodialysis enables some motivated patients to return to the workforce or to further education.[i]
Stephen Furst's successful career as an actor and director includes his most famous role as Flounder in the movie "Animal House." He has also appeared in television shows such as "St. Elsewhere" and "Babylon 5,"and provided character voices for animated films including "Little Mermaid II" and "Buzz Lightyear of Star Command." Joe Collins is a Massachusetts State Trooper who attributes his ability to continue working at this high-pressure, unpredictable job thanks to more frequent, at-home therapy with the System One, and receiving a kidney transplant in 2012. Dr. George Williams is a physician who was unable to work while receiving conventional, in-center hemodialysis therapy. After switching to more frequent home hemodialysis with the NxStage System One four years ago, he is now able to work again. The educational discussion among Furst, Collins and Williams will take place on Sunday, March 10 from 7:00 to 9:00 p.m. in Princessa & Foyer at the Grand Hyatt in Seattle during ADC.
"ADC is a tremendous event that enables the pioneers of renal care to come together, learn, share and work to improve the lives of people with kidney disease," says Jeffrey H. Burbank, Chief Executive Officer of NxStage. "We look forward to working with Stephen Furst, Joe Collins, Dr. George Williams and other patients and physicians to continue educating the renal community about the benefits of more frequent home hemodialysis. We are honored to play a critical role in helping dialysis patients lead healthier and more productive lives."
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). The System One also has a CE mark and has been cleared by Health Canada. Its simplicity and revolutionary size (just over a foot tall) provide convenient use in patients' homes and give patients the freedom to travel with their therapy. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on the road.
About NxStage Medical
NxStage is a medical device company, headquartered in Lawrence, MA, USA, which develops, manufactures, and markets innovative systems for the treatment of end-stage renal disease (ESRD), and acute kidney failure. The System One home hemodialysis device developed by NxStage is the only FDA approved portable hemodialysis machine cleared for home use. For more information on NxStage, or NxStage products, visit, http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq. VP, Investor Relations firstname.lastname@example.org
[i] Kraus MA, Cox CG, Summitt CL, et al. Work and travel in a large Short Daily Hemodialysis (SDHD) program. Abstract presented at American Society of Nephrology Annual Conference, 2007.
Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis. 2003;42(5):1020-1035.
Heidenheim PA, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis. 2003;42(S1)(S1):S36-S41.
Borg D, Weinstein D, NcNeil C, et al. Home dialysis: the future is now. Abstract presented at the Annual Dialysis Conference, 2008.
Lindsay RM. Daily hemodialysis: the time has come? Am J Kidney Dis. 2005;45(5):793-797.
SOURCE NxStage Medical, Inc.